Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine.

PHASE2CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

December 28, 2017

Primary Completion Date

May 26, 2018

Study Completion Date

December 28, 2018

Conditions
Polio and Post-Polio Syndrome
Interventions
BIOLOGICAL

Three-dose regimen of high dosage investigational sIPV

The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..

BIOLOGICAL

Three-dose regimen of medium dosage investigational sIPV

The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..

BIOLOGICAL

Three-dose regimen of low dosage investigational sIPV

The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..

BIOLOGICAL

Three-dose regimen of commercialized sIPV

The control vaccine was manufactured by Chinese Academy of Medical Sciences.

BIOLOGICAL

Three-dose regimen of commercialized IPV

The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).

Trial Locations (1)

210009

Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing

Sponsors
All Listed Sponsors
collaborator

Beijing Minhai Biotechnology Co., Ltd

INDUSTRY

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK